Drug intelligence / Profile preview

YE-NEO-011

Development stage: Unknown
Lead developer: NantBioScience
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

YE-NEO-011 is an investigational, personalized neoepitope yeast-based vaccine developed by Nantbio (a NANT company) for the treatment of advanced solid tumors. The vaccine utilizes a heat-killed *Saccharomyces cerevisiae* yeast platform engineered to express patient-specific neoantigens identified through genomic sequencing of the patient's tumor. By delivering these unique neoepitopes, YE-NEO-011 is designed to stimulate a targeted T-cell mediated immune response against the tumor. It received FDA authorization for clinical trials in 2018 and is currently being evaluated in Phase 1 studies for various cancers, including digestive and metabolic-related malignancies.

Targets

pMHC (Peptide-MHC complex family)

Beyond the preview

Go deeper on YE-NEO-011.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YE-NEO-011.

Explore the full profile